OS Therapies (NYSEAMERICAN:OSTX) Stock Jumps 0.6% – Should You Buy?

Shares of OS Therapies Incorporated (NYSEAMERICAN:OSTX) were up 0.6% during mid-day trading on Friday. The stock traded as high as $1.66 and last traded at $1.62. Approximately 231,498 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 712,240 shares. The stock had previously closed at $1.61.

Wall Street Analysts Forecast Growth

Separately, Roth Capital began coverage on OS Therapies in a research report on Thursday, July 9th. They issued a “buy” rating and a $7.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, OS Therapies currently has an average rating of “Moderate Buy” and an average target price of $13.33.

OS Therapies Trading Up 0.6%

The company has a fifty day simple moving average of $1.65 and a two-hundred day simple moving average of $1.64. The company has a market cap of $74.73 million, a PE ratio of -1.49 and a beta of -0.64.

OS Therapies (NYSEAMERICAN:OSTX) last issued its earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter. On average, research analysts anticipate that OS Therapies Incorporated will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently bought a new position in OS Therapies stock. AXQ Capital LP purchased a new stake in OS Therapies Incorporated (NYSEAMERICAN:OSTX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 24,623 shares of the company’s stock, valued at approximately $47,000. AXQ Capital LP owned approximately 0.05% of OS Therapies at the end of the most recent reporting period.

OS Therapies Company Profile

OS Therapies, Inc is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults, as well as other solid tumors. The company’s work is aimed at addressing significant unmet medical needs in cancers for which treatment options remain limited.

Its lead investigational product, OST-HER2, is an immunotherapy designed to target tumors that express the HER2 protein. OS Therapies has been evaluating OST-HER2 in clinical studies involving patients with recurrent or metastatic osteosarcoma.